Tilak Healthcare announced today that it entered into a framework agreement with Novartis (NYSE:NVS) to promote its OdySight remote monitoring app.
Paris-based Tilak’s OdySight is a smartphone application designed to monitor and engage patients with age-related chronic eye diseases. The app is available by prescription and includes vision tests and puzzles to boost engagement while strengthening the patient-client relationship, according to a news release.
The two companies plan to use the collaboration to make OdySight a well-known and accessible option for many more patients through the expansion of co-promotion around the globe. Tilak launched a joint promotion with Novartis France in 2019.
“We welcome this collaboration with Tilak Healthcare,” Novartis Pharma AG franchise head of ophthalmology Nikos Tripodis said in the release. “During the unprecedented health crisis, Novartis is committed to facilitating the patient care journey. It is with this in mind that Novartis has partnered with Tilak Healthcare to promote OdySight.”
“We are pleased to embark on this journey alongside Novartis Pharma AG, which has a long history of providing innovative solutions for patients,” Tilak Healthcare CEO Edouard Gasser added. “Thanks to this partnership, Tilak Healthcare will make OdySight accessible to a lot more people and will help optimize the current healthcare process. The current exceptional circumstances reinforce our belief in the usefulness of clinically validated digital tools for optimizing remote patient monitoring and building tomorrow’s healthcare system.”
